These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3169120)

  • 1. Apparent mendelian recessive inheritance of sparteine metabolism in an extended Japanese family.
    Chiba K; Kato J; Hashimoto K; Ishizaki T
    Eur J Clin Pharmacol; 1988; 34(6):661-2. PubMed ID: 3169120
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
    Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I
    Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic polymorphism of sparteine metabolism.
    Eichelbaum M; Reetz KP; Schmidt EK; Zekorn C
    Xenobiotica; 1986 May; 16(5):465-81. PubMed ID: 3739368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for polymorphic oxidation of sparteine in Japanese subjects.
    Ishizaki T; Eichelbaum M; Horai Y; Hashimoto K; Chiba K; Dengler HJ
    Br J Clin Pharmacol; 1987 Apr; 23(4):482-5. PubMed ID: 3580254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A human genetic defect in the metabolism of sparteine].
    Spannbrucker N; Eichelbaum M; Steinke B; Dengler HJ
    Verh Dtsch Ges Inn Med; 1978; (84):1125-7. PubMed ID: 741903
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.
    Yokota H; Tamura S; Furuya H; Kimura S; Watanabe M; Kanazawa I; Kondo I; Gonzalez FJ
    Pharmacogenetics; 1993 Oct; 3(5):256-63. PubMed ID: 8287064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
    Eichelbaum M; Spannbrucker N; Steincke B; Dengler HJ
    Eur J Clin Pharmacol; 1979 Sep; 16(3):183-7. PubMed ID: 499318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype.
    Yokoi T; Kosaka Y; Chida M; Chiba K; Nakamura H; Ishizaki T; Kinoshita M; Sato K; Gonzalez FJ; Kamataki T
    Pharmacogenetics; 1996 Oct; 6(5):395-401. PubMed ID: 8946471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
    Madsen H; Hansen TS; Brøsen K
    Pharmacogenetics; 1996 Dec; 6(6):513-9. PubMed ID: 9014200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
    Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
    J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
    Meyer UA; Skoda RC; Zanger UM
    Pharmacol Ther; 1990; 46(2):297-308. PubMed ID: 2181495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sparteine oxidation polymorphism: a family study.
    Brøsen K; Otton SV; Gram LF
    Br J Clin Pharmacol; 1986 Jun; 21(6):661-7. PubMed ID: 3741716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
    Drøhse A; Bathum L; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two novel mutations in the EYS gene are possible major causes of autosomal recessive retinitis pigmentosa in the Japanese population.
    Hosono K; Ishigami C; Takahashi M; Park DH; Hirami Y; Nakanishi H; Ueno S; Yokoi T; Hikoya A; Fujita T; Zhao Y; Nishina S; Shin JP; Kim IT; Yamamoto S; Azuma N; Terasaki H; Sato M; Kondo M; Minoshima S; Hotta Y
    PLoS One; 2012; 7(2):e31036. PubMed ID: 22363543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
    Lennard MS; Iyun AO; Jackson PR; Tucker GT; Woods HF
    Pharmacogenetics; 1992 Apr; 2(2):89-92. PubMed ID: 1302046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of polymorphism of sparteine oxidation in the South African Venda.
    Sommers DK; Moncrieff J; Avenant JC
    Hum Exp Toxicol; 1991 May; 10(3):175-8. PubMed ID: 1678945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sparteine metabolism in a Nigerian population.
    Ritchie JC; Mitchell SC; Smith RL
    Drug Metabol Drug Interact; 1996; 13(2):129-35. PubMed ID: 8905244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.
    Mikus G; Ha HR; Vozeh S; Zekorn C; Follath F; Eichelbaum M
    Eur J Clin Pharmacol; 1986; 31(1):69-72. PubMed ID: 3780830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R; Meyer UA
    Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.